Pay in 4 interest-free payments of $7.26 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
Approved in November 2023, Zepbound represents a novel therapeutic approach that combines dual agonist activity at both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors
Stanford's Department of Psychiatry and Behavioral Sciences also supported the work.
Caffeine from All Sources: 160 mg per can
Indications Semaglutide is a prescription GLP-1 receptor agonist indicated: As an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with a body mass index (BMI) 30 kg/m (obesity), or 27 kg/m (overweight) in the presence of at least one weight-related comorbidity (e.g., hypertension, type 2 diabetes, or dyslipidemia)
.png)
US$ 27.10
US$ 28.66
US$ 20.73
